Clinical Trial to Evaluate Efficacy and Safety of SID142 in Patients With Chronic Artery Occlusive Disease
Status:
Completed
Trial end date:
2018-10-15
Target enrollment:
Participant gender:
Summary
Rinexin® Tab (Cilostazol 100mg, Ginkgo biloba leaf extract 80mg) has been widely used as an
anti-platelet agent for the treatment of PAD. SID142 is a new controlled-release product
improved patient's convenience and disadvantage of dosage regimen of previous drug. The aim
of this study was to compare the efficacy and safety of SID142 and Rinexin® Tab in patients
with PAD